Total Payments
$451,051
2024 Payments
$45,988
Companies
18
Transactions
164
Payment Breakdown by Category
Consulting$418,946 (92.9%)
Travel$18,240 (4.0%)
Research$5,967 (1.3%)
Other$4,540 (1.0%)
Food & Beverage$2,884 (0.6%)
Gifts$475.00 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $418,946 | 85 | 92.9% |
| Travel and Lodging | $18,240 | 24 | 4.0% |
| Unspecified | $5,967 | 11 | 1.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3,790 | 4 | 0.8% |
| Food and Beverage | $2,884 | 38 | 0.6% |
| Honoraria | $750.00 | 1 | 0.2% |
| Gift | $475.00 | 1 | 0.1% |
Payments by Type
General
$445,084
153 transactions
Research
$5,967
11 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Boehringer Ingelheim b.v. | $250,125 | 15 | $0 (2018) |
| Intercept Pharmaceuticals, Inc. | $48,166 | 24 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $41,713 | 43 | $0 (2024) |
| Alnylam Pharmaceuticals Inc. | $37,083 | 25 | $0 (2024) |
| Boehringer Ingelheim International GmbH | $22,655 | 11 | $0 (2024) |
| Eli Lilly and Company | $14,795 | 7 | $0 (2023) |
| GlaxoSmithKline, LLC. | $8,264 | 3 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $7,544 | 7 | $0 (2024) |
| AMAG Pharmaceuticals, Inc. | $5,100 | 1 | $0 (2023) |
| VERTEX PHARMACEUTICALS INCORPORATED | $3,258 | 4 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $45,988 | 34 | Boehringer Ingelheim International GmbH ($21,064) |
| 2023 | $48,790 | 39 | Alnylam Pharmaceuticals Inc. ($22,666) |
| 2022 | $70,497 | 37 | Intercept Pharmaceuticals, Inc. ($42,199) |
| 2021 | $27,639 | 23 | Bayer HealthCare Pharmaceuticals Inc. ($14,011) |
| 2020 | $6,320 | 10 | Fresenius USA Marketing, Inc. ($2,920) |
| 2018 | $81,955 | 5 | Boehringer Ingelheim b.v. ($81,875) |
| 2017 | $169,862 | 16 | Boehringer Ingelheim b.v. ($168,250) |
All Payment Transactions
164 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Intercept Pharmaceuticals, Inc. | OCALIVA (Drug) | — | Cash or cash equivalent | $166.66 | Research |
| Study: Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) • Category: Hepatology / Gastroenterology | ||||||
| 12/15/2024 | Alnylam Pharmaceuticals Inc. | — | Consulting Fee | Cash or cash equivalent | $416.66 | General |
| 11/20/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Consulting Fee | Cash or cash equivalent | $1,837.50 | General |
| Category: Cardio-renal | ||||||
| 11/15/2024 | Alnylam Pharmaceuticals Inc. | — | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| 11/07/2024 | Intercept Pharmaceuticals, Inc. | OCALIVA (Drug) | — | Cash or cash equivalent | $166.66 | Research |
| Study: Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) • Category: Hepatology / Gastroenterology | ||||||
| 10/16/2024 | VERTEX PHARMACEUTICALS INCORPORATED | — | Consulting Fee | Cash or cash equivalent | $141.66 | General |
| 10/15/2024 | Alnylam Pharmaceuticals Inc. | — | Consulting Fee | Cash or cash equivalent | $999.98 | General |
| 09/15/2024 | Alnylam Pharmaceuticals Inc. | — | Consulting Fee | Cash or cash equivalent | $666.66 | General |
| 08/14/2024 | Alnylam Pharmaceuticals Inc. | — | Consulting Fee | Cash or cash equivalent | $1,166.62 | General |
| 08/14/2024 | VERTEX PHARMACEUTICALS INCORPORATED | — | Consulting Fee | Cash or cash equivalent | $141.66 | General |
| 07/12/2024 | Novartis Pharmaceuticals Corporation | — | Consulting Fee | Cash or cash equivalent | $6,812.50 | General |
| 07/12/2024 | Alnylam Pharmaceuticals Inc. | — | Consulting Fee | Cash or cash equivalent | $833.30 | General |
| 07/12/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $225.00 | General |
| 07/12/2024 | Novartis Pharmaceuticals Corporation | — | Travel and Lodging | In-kind items and services | $210.90 | General |
| 07/12/2024 | Novartis Pharmaceuticals Corporation | — | Travel and Lodging | Cash or cash equivalent | $67.00 | General |
| 07/12/2024 | Novartis Pharmaceuticals Corporation | — | Travel and Lodging | In-kind items and services | $50.00 | General |
| 07/12/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $32.17 | General |
| 07/11/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $146.66 | General |
| 06/13/2024 | Alnylam Pharmaceuticals Inc. | — | Consulting Fee | Cash or cash equivalent | $1,333.28 | General |
| 05/29/2024 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $8,100.00 | General |
| 05/29/2024 | Boehringer Ingelheim International GmbH | — | Travel and Lodging | In-kind items and services | $221.66 | General |
| 05/29/2024 | Boehringer Ingelheim International GmbH | — | Food and Beverage | In-kind items and services | $18.90 | General |
| 05/29/2024 | Boehringer Ingelheim International GmbH | — | Food and Beverage | In-kind items and services | $6.90 | General |
| 05/14/2024 | Alnylam Pharmaceuticals Inc. | — | Consulting Fee | Cash or cash equivalent | $833.32 | General |
| 04/23/2024 | Boehringer Ingelheim International GmbH | — | Travel and Lodging | In-kind items and services | $12,208.13 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) | INTERCEPT PHARMACEUTICALS, INC. | $5,633 | 9 |
| Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) | Intercept Pharmaceuticals, Inc. | $333.32 | 2 |
About Dr. Sankar Navaneethan, MD
Dr. Sankar Navaneethan, MD is a Nephrology healthcare provider based in Cleveland, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/21/2006. The National Provider Identifier (NPI) number assigned to this provider is 1750480562.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Sankar Navaneethan, MD has received a total of $451,051 in payments from pharmaceutical and medical device companies, with $45,988 received in 2024. These payments were reported across 164 transactions from 18 companies. The most common payment nature is "Consulting Fee" ($418,946).
Ad
Practice Information
- Specialty Nephrology
- Location Cleveland, OH
- Active Since 09/21/2006
- Last Updated 10/21/2011
- Taxonomy Code 207RN0300X
- Entity Type Individual
- NPI Number 1750480562
Products in Payments
- TRADJENTA (Drug) $250,125
- OCALIVA (Drug) $48,166
- Kerendia (Drug) $35,075
- Non-Covered $6,638
- JARDIANCE (Drug) $4,340
- LOKELMA (Drug) $3,890
- Veltassa (Drug) $200.00
- TARPEYO (Drug) $46.95
- Repatha (Biological) $44.95
- Auryxia (Drug) $31.75
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Nephrology Doctors in Cleveland
Dr. Titte Srinivas, Md, MD
Nephrology — Payments: $227,685
Nephrology $227,685
Dr. Georges Nakhoul, M.d, M.D
Nephrology — Payments: $159,362
Nephrology $159,362
Sevag Demirjian, Md, MD
Nephrology — Payments: $151,400
Nephrology $151,400
Amitkumar Patel, M.d, M.D
Nephrology — Payments: $68,997
Nephrology $68,997
Dr. James Simon, M.d, M.D
Nephrology — Payments: $63,895
Nephrology $63,895
Emilio Poggio, Md, MD
Nephrology — Payments: $47,784
Nephrology $47,784